FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3017057237> ?p ?o ?g. }

• W3017057237 endingPage "1937" @default.
• W3017057237 startingPage "1928" @default.
• W3017057237 abstract "PURPOSE The combination of lenalidomide, bortezomib, and dexamethasone (RVD) is a highly effective and convenient induction regimen for both transplantation-eligible and -ineligible patients with myeloma. Here, we present the largest cohort of patients consecutively treated with RVD induction therapy followed by risk-adapted maintenance therapy with the longest follow-up and important information on long-term outcomes. PATIENTS AND METHODS We describe 1,000 consecutive patients with newly diagnosed myeloma treated with RVD induction therapy from January 2007 until August 2016. Demographic and clinical characteristics and outcomes data were obtained from our institutional review board–approved myeloma database. Responses and progression were evaluated per International Myeloma Working Group Uniform Response Criteria. RESULTS The overall response rate was 97.1% after induction therapy and 98.5% after transplantation, with 89.9% of patients achieving a very good partial response (VGPR) or better and 33.3% achieving stringent complete response after transplantation at a median follow-up time of 67 months. The estimated median progression-free survival time was 65 months (95% CI, 58.7 to 71.3 months) for the entire cohort, 40.3 months (95% CI, 33.5 to 47 months) for high-risk patients, and 76.5 months (95% CI, 66.9 to 86.2 months) for standard-risk patients. The median overall survival (OS) time for the entire cohort was 126.6 months (95% CI, 113.3 to 139.8 months). The median OS for high-risk patients was 78.2 months (95% CI, 62.2 to 94.2 months), whereas it has not been reached for standard-risk patients. Five-year OS rates for high-risk and standard-risk patients were 57% and 81%, respectively, and the 10-year OS rates were 29% and 58%, respectively. CONCLUSION RVD is an induction regimen that delivers high response rates (VGPR or better) in close to 90% of patients after transplantation, and risk-adapted maintenance can deliver unprecedented long-term outcomes. This study includes the largest cohort of patients treated with RVD reported to date with long follow-up and demonstrates the ability of 3-drug induction regimens in patients with newly diagnosed multiple myeloma to result in a substantial survival benefit." @default.
• W3017057237 created "2020-04-24" @default.
• W3017057237 creator A5007228982 @default.
• W3017057237 creator A5016626239 @default.
• W3017057237 creator A5021230077 @default.
• W3017057237 creator A5022264517 @default.
• W3017057237 creator A5022520524 @default.
• W3017057237 creator A5023276777 @default.
• W3017057237 creator A5038076013 @default.
• W3017057237 creator A5064293376 @default.
• W3017057237 creator A5077897003 @default.
• W3017057237 creator A5088696429 @default.
• W3017057237 date "2020-06-10" @default.
• W3017057237 modified "2023-10-10" @default.
• W3017057237 title "Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma" @default.
• W3017057237 cites W1986297232 @default.
• W3017057237 cites W2029204292 @default.
• W3017057237 cites W2125721471 @default.
• W3017057237 cites W2128084036 @default.
• W3017057237 cites W2143425592 @default.
• W3017057237 cites W2604776612 @default.
• W3017057237 cites W2737964630 @default.
• W3017057237 cites W2972305086 @default.
• W3017057237 cites W2985459251 @default.
• W3017057237 cites W2987636176 @default.
• W3017057237 cites W2987834777 @default.
• W3017057237 doi "https://doi.org/10.1200/jco.19.02515" @default.
• W3017057237 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7587409" @default.
• W3017057237 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32298201" @default.
• W3017057237 hasPublicationYear "2020" @default.
• W3017057237 type Work @default.
• W3017057237 sameAs 3017057237 @default.
• W3017057237 citedByCount "125" @default.
• W3017057237 countsByYear W30170572372020 @default.
• W3017057237 countsByYear W30170572372021 @default.
• W3017057237 countsByYear W30170572372022 @default.
• W3017057237 countsByYear W30170572372023 @default.
• W3017057237 crossrefType "journal-article" @default.
• W3017057237 hasAuthorship W3017057237A5007228982 @default.
• W3017057237 hasAuthorship W3017057237A5016626239 @default.
• W3017057237 hasAuthorship W3017057237A5021230077 @default.
• W3017057237 hasAuthorship W3017057237A5022264517 @default.
• W3017057237 hasAuthorship W3017057237A5022520524 @default.
• W3017057237 hasAuthorship W3017057237A5023276777 @default.
• W3017057237 hasAuthorship W3017057237A5038076013 @default.
• W3017057237 hasAuthorship W3017057237A5064293376 @default.
• W3017057237 hasAuthorship W3017057237A5077897003 @default.
• W3017057237 hasAuthorship W3017057237A5088696429 @default.
• W3017057237 hasBestOaLocation W30170572372 @default.
• W3017057237 hasConcept C126322002 @default.
• W3017057237 hasConcept C141071460 @default.
• W3017057237 hasConcept C2776063141 @default.
• W3017057237 hasConcept C2776364478 @default.
• W3017057237 hasConcept C2776694085 @default.
• W3017057237 hasConcept C2777478702 @default.
• W3017057237 hasConcept C2778283404 @default.
• W3017057237 hasConcept C2779050716 @default.
• W3017057237 hasConcept C2780401358 @default.
• W3017057237 hasConcept C2781413609 @default.
• W3017057237 hasConcept C2911091166 @default.
• W3017057237 hasConcept C2991767035 @default.
• W3017057237 hasConcept C71924100 @default.
• W3017057237 hasConcept C72563966 @default.
• W3017057237 hasConceptScore W3017057237C126322002 @default.
• W3017057237 hasConceptScore W3017057237C141071460 @default.
• W3017057237 hasConceptScore W3017057237C2776063141 @default.
• W3017057237 hasConceptScore W3017057237C2776364478 @default.
• W3017057237 hasConceptScore W3017057237C2776694085 @default.
• W3017057237 hasConceptScore W3017057237C2777478702 @default.
• W3017057237 hasConceptScore W3017057237C2778283404 @default.
• W3017057237 hasConceptScore W3017057237C2779050716 @default.
• W3017057237 hasConceptScore W3017057237C2780401358 @default.
• W3017057237 hasConceptScore W3017057237C2781413609 @default.
• W3017057237 hasConceptScore W3017057237C2911091166 @default.
• W3017057237 hasConceptScore W3017057237C2991767035 @default.
• W3017057237 hasConceptScore W3017057237C71924100 @default.
• W3017057237 hasConceptScore W3017057237C72563966 @default.
• W3017057237 hasIssue "17" @default.
• W3017057237 hasLocation W30170572371 @default.
• W3017057237 hasLocation W30170572372 @default.
• W3017057237 hasOpenAccess W3017057237 @default.
• W3017057237 hasPrimaryLocation W30170572371 @default.
• W3017057237 hasRelatedWork W2470933183 @default.
• W3017057237 hasRelatedWork W2530787370 @default.
• W3017057237 hasRelatedWork W2546436011 @default.
• W3017057237 hasRelatedWork W2972305086 @default.
• W3017057237 hasRelatedWork W2981207131 @default.
• W3017057237 hasRelatedWork W3025827814 @default.
• W3017057237 hasRelatedWork W3134875278 @default.
• W3017057237 hasRelatedWork W4206235322 @default.
• W3017057237 hasRelatedWork W4284886781 @default.
• W3017057237 hasRelatedWork W4313493220 @default.
• W3017057237 hasVolume "38" @default.
• W3017057237 isParatext "false" @default.
• W3017057237 isRetracted "false" @default.
• W3017057237 magId "3017057237" @default.
• W3017057237 workType "article" @default.